Earnings call transcript: Columbus McKinnon Q4 2026 sees EPS miss, revenue beat

Columbus McKinnon posted mixed Q4 fiscal 2026 results, missing EPS by 48.9% at $0.24 versus $0.47 expected, while revenue beat by 16.8% at $437.83 million. The stock fell 11.9% pre-market, even as management highlighted record FY2026 net sales of $1.2 billion, 93% adjusted EBITDA growth in Q4, and FY2027 guidance for $1.70-$1.90 EPS and $2.05-$2.12 billion in sales. The outlook remains supported by Kito Crosby integration synergies, but margins face pressure from tariffs, inflation, and geopolitical disruption in EMEA.

Analysis

The selloff is more informative than the headline miss: this is a de-risking event around an integration story, not a demand collapse. CMCO is now a levered blend of a cyclical industrial business and a freshly acquired asset with noisy purchase-accounting, restructuring, tariff, and interest costs all landing at once; that combination can depress reported earnings for several quarters even if the operating run-rate is improving. The key second-order issue is that the market is likely extrapolating a one-quarter GAAP shock into a broken balance sheet narrative, which is exactly when forced multiple compression tends to overshoot.

The real fundamental test is not next quarter EPS, but whether management can turn the enlarged revenue base into cash fast enough to hit deleveraging milestones. If they do, the equity can rerate sharply because the current setup has the classic ingredients for a fast sentiment reversal: backlog visibility, stated price-through, and synergies that are front-loaded in action but back-loaded in reported earnings. The risk is that Europe/Middle East weakness and mix drag persist longer than expected, making the FY27 margin bridge look like a perpetual promise instead of a near-term catalyst.

Consensus is probably underestimating how much of the margin weakness is temporary accounting and transition noise versus true end-market deterioration. The stock is already near technical support, so the market is paying a low price for a situation where even modest synergy execution and debt reduction can change the equity story quickly over the next 2-3 quarters. The contrarian takeaway: this is more a timing problem than a thesis break, but only if cash conversion improves before investors lose patience with the integration timeline.

Key Decisions for Investors

• Buy CMCO common on weakness only if it holds the current support zone for 1-2 sessions; target 20-30% upside over 3-6 months if deleveraging and synergy delivery stay on track, with a hard stop if guidance is cut or backlog rolls over.
• Pair trade: long CMCO / short a higher-multiple industrial peer with similar cycle exposure over the next 1-2 quarters; the setup monetizes valuation compression versus an earnings normalization trade.
• For event-driven investors, buy CMCO call spreads 3-6 months out to express upside on a post-integration rerating while limiting downside if Europe/Middle East weakness lingers.
• Avoid adding until the market sees one clean quarter of working-capital improvement and debt paydown; the next catalyst is cash flow, not revenue.
• If you want a hedge against a failed integration, short CMCO against a basket of self-help industrials; the short only works if margin expansion proves slower than management's 2H27 setup.